Azz Inc (AZZ) · Oct 26, 2026 · Other events
FY2032 targets — $3.0B sales and 23% Adjusted EBITDA margin by FY2032
AZZ’s investor presentation mostly repackages its October 13 guidance raise while adding a longer-term $3 billion sales and 23% margin ambition.
AZZ is a North American hot-dip galvanizing and coil-coating operator in a growth-and-deleveraging phase, using strong Metal Coatings momentum, the Washington, Missouri plant ramp, and recent Seattle Galvanizing acquisition to extend FY2027 growth. Its October 13, 2026 second-quarter release had already reported record quarterly sales and raised FY2027 guidance, so this October 26 presentation is primarily a broader investor narrative rather than a fresh operating update.
The filing mostly confirms an already-known outlook. The presentation repeats the FY2027 guidance revised on October 13, lifting sales to $1.825–$1.875 billion, Adjusted EBITDA to $380–$420 million, and Adjusted diluted EPS to $7.00–$7.30 from the prior ranges of $1.80–$1.85 billion, $375–$415 million, and $6.75–$7.15, respectively. 〔0〕 Because the raise was already public before this filing, the presentation itself adds limited surprise.
| Metric | FY2026 actual / TTM | FY2027 revised guidance or current figure | Longer-term target |
|---|---|---|---|
| Sales | $1.65B FY2026; $1.75B TTM | $1.825–$1.875B | $3.0B by FY2032 |
| Adjusted EBITDA | $367.6M FY2026; $383M TTM | $380–$420M | 23% margin by FY2032 |
| Adjusted diluted EPS | $6.19 FY2026 | $7.00–$7.30 | 15% CAGR goal |
| Net leverage | 1.3x TTM FY2027 | $100–$140M planned debt reduction | ~0.5x–1.5x target range |
The genuinely incremental message is the length of the runway. AZZ now frames the business around a decade-long compounding model combining 5–7% organic growth, 3–5% M&A growth, and margin expansion from roughly 22% currently toward 23%. The filing states, “FY 2032 Goals: Sales $3.0B and Adjusted EBITDA 23%.” That is a strategic ambition, not a new commitment or near-term forecast, so it strengthens the narrative more than it changes the current earnings baseline.
Execution risk is concentrated in a few identifiable growth projects. The Washington facility is expected to be accretive in FY2027, with 75% of new capacity committed under multi-year take-or-pay contracts and only $1.4 million of remaining capital spending. 〔1〕 Those details make the ramp look better protected than a purely speculative greenfield build, while the 1.3x net leverage position preserves room for debt reduction, acquisitions, and shareholder returns.
Bottom line: This filing extends AZZ’s growth story but does not materially reset it. The near-term guidance raise was already known; the new contribution is a more ambitious long-term framework, with the Washington ramp as the main proof point still ahead.
Washington plant FY2027 ramp and earnings accretion
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!